The Inflation Reduction Act signed into law in August 2022, resulted in groundbreaking changes in the U.S. pharmaceuticals industry that will happen over the next 5 years; 2026 to 2029. The two main components of the legislation aim to reform Medicare's drug-pricing policy: price negotiations and higher inflationary cap price. With blockbuster cancer care drugs on the targeted negotiation list the macro impact of the IRA on cancer care pharmaceutical industry over the next 5 years will be explored. Discussion will focus on potential unintended implications of the Inflation Reduction Act (IRA)’s resulting from the CMS drug price negotiation efforts. The panel will offer insights into navigating the IRA including implementation strategies over the near and longer term.
Session Objectives
- Understand the financial impact of IRA on Pharma Industry
- Impact on M&A Activity
- How will drug launches Ahead look
- Will Innovation be hurt
- Will cures and development be stifled
- How will contracting happen
